Baseline characteristics
| Characteristic . | λ (n = 404) . | κ (n = 153) . | P . |
|---|---|---|---|
| Age, median (IQR), y | 59 (53-65) | 59 (53-64) | .83 |
| Male, % | 62 | 64 | .69 |
| Organs involved, n (%) | |||
| Cardiac | 198 (49) | 64 (41) | .15 |
| Renal | 277 (69) | 88 (57) | .02 |
| Hepatic | 29 (7) | 28 (18) | .0003 |
| Neurologic | 66 (16) | 14 (9) | .03 |
| Other | 92 (23) | 46 (30) | .08 |
| >2 organs involved | 57 (14) | 20 (13) | .89 |
| BMPCs, median (IQR), % | 8 (5-13) | 8 (5-15) | .84 |
| BMPCs ≥10%, n (%) | 164 (41) | 61 (40) | 1 |
| Monoclonal protein, n (%) | |||
| IgG | 139 (34) | 53 (35) | 1 |
| IgA | 47 (12) | 5 (3) | .0017 |
| IgM | 14 (3) | 12 (8) | .04 |
| IgD | 5 (1) | 1 (<1) | 1 |
| Light chain only | 199 (49) | 82 (54) | .39 |
| Creatinine, median (IQR), mg/dL | 1.0 (0.9-1.2) | 1.1 (0.9-1.5) | .0022 |
| ALP, median (IQR), U/L | 81 (65-110) | 89 (69-134) | .01 |
| NT-Pro BNP, median (IQR), pg/mL | 499 (157-1903) | 514 (163-2119) | .79 |
| Troponin T, median (IQR), ng/mL | 0.01 (0.01-0.02) | 0.01 (0.01-0.03) | .65 |
| dFLC, median (IQR), ng/mL | 11.5 (5.2-33.8) | 21.3 (5.9-65.2) | .0049 |
| dFLC >5 mg/dL, n (%) | 272 (76) | 104 (78) | .81 |
| dFLC >18 mg/dL, n (%) | 138 (36) | 70 (52) | .0076 |
| 24-h urine protein (IQR), g | 3.4 (0.2-7.2) | 0.96 (0.2-5.4) | .0026 |
| Mayo stage 2004, n (%) | .88 | ||
| I | 227 (66) | 87 (67) | |
| II | 59 (17) | 20 (15) | |
| III | 60 (17) | 24 (18) | |
| Missing | 58 | 22 | |
| Mayo stage 2012, n (%) | .16 | ||
| I | 159 (47) | 46 (36) | .03 |
| II | 95 (28) | 47 (36) | |
| III | 51 (15) | 22 (17) | |
| IV | 36 (10) | 14 (11) | |
| Missing | 63 | 24 |
| Characteristic . | λ (n = 404) . | κ (n = 153) . | P . |
|---|---|---|---|
| Age, median (IQR), y | 59 (53-65) | 59 (53-64) | .83 |
| Male, % | 62 | 64 | .69 |
| Organs involved, n (%) | |||
| Cardiac | 198 (49) | 64 (41) | .15 |
| Renal | 277 (69) | 88 (57) | .02 |
| Hepatic | 29 (7) | 28 (18) | .0003 |
| Neurologic | 66 (16) | 14 (9) | .03 |
| Other | 92 (23) | 46 (30) | .08 |
| >2 organs involved | 57 (14) | 20 (13) | .89 |
| BMPCs, median (IQR), % | 8 (5-13) | 8 (5-15) | .84 |
| BMPCs ≥10%, n (%) | 164 (41) | 61 (40) | 1 |
| Monoclonal protein, n (%) | |||
| IgG | 139 (34) | 53 (35) | 1 |
| IgA | 47 (12) | 5 (3) | .0017 |
| IgM | 14 (3) | 12 (8) | .04 |
| IgD | 5 (1) | 1 (<1) | 1 |
| Light chain only | 199 (49) | 82 (54) | .39 |
| Creatinine, median (IQR), mg/dL | 1.0 (0.9-1.2) | 1.1 (0.9-1.5) | .0022 |
| ALP, median (IQR), U/L | 81 (65-110) | 89 (69-134) | .01 |
| NT-Pro BNP, median (IQR), pg/mL | 499 (157-1903) | 514 (163-2119) | .79 |
| Troponin T, median (IQR), ng/mL | 0.01 (0.01-0.02) | 0.01 (0.01-0.03) | .65 |
| dFLC, median (IQR), ng/mL | 11.5 (5.2-33.8) | 21.3 (5.9-65.2) | .0049 |
| dFLC >5 mg/dL, n (%) | 272 (76) | 104 (78) | .81 |
| dFLC >18 mg/dL, n (%) | 138 (36) | 70 (52) | .0076 |
| 24-h urine protein (IQR), g | 3.4 (0.2-7.2) | 0.96 (0.2-5.4) | .0026 |
| Mayo stage 2004, n (%) | .88 | ||
| I | 227 (66) | 87 (67) | |
| II | 59 (17) | 20 (15) | |
| III | 60 (17) | 24 (18) | |
| Missing | 58 | 22 | |
| Mayo stage 2012, n (%) | .16 | ||
| I | 159 (47) | 46 (36) | .03 |
| II | 95 (28) | 47 (36) | |
| III | 51 (15) | 22 (17) | |
| IV | 36 (10) | 14 (11) | |
| Missing | 63 | 24 |
Only results for patients with renal involvement are included in the analysis.
ALP, alkaline phosphatase; IQR, interquartile range.